Competency information
Details
Perform whole genome analysis on samples from patients with leukaemia at diagnosis.
- Examples CML, ALL and AML.
Considerations
- Use of ISCN for malignancy analysis
- The local guidance for whole genome analysis from patients with Leukaemia.
- Best practice guidelines, national/international guidance and QA (external and internal).
- Selection and analysis in mixed cell populuations
- Validation and verification of findings
- Prognostic and diagnostic genetic markers.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 | Outcome Apply appropriate sample selection criteria, taking into account the implications of acquired sporadic cancer with respect to sampling mixed cell populations, limits of detection, sensitivity of assay and patient management. |
| # 2 | Outcome Apply an appropriate testing strategy for the commonly referred acquired sporadic cancers at all stages of the patient pathway. |
| # 4 | Outcome Perform whole genome testing for patients referred with sporadic cancer. |